X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-09-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $45.73 | -5,000 | 146,202 | -3% | -$228,658 | |||||
| D | 2024-09-11 | RNA | Flanagan W. Michael | CSTO | S - Sale+OE | $40.40 | -111,394 | 60,871 | -65% | -$4,500,244 | |||||
| D | 2024-09-11 | RNA | McCarthy Teresa | CHRO | S - Sale+OE | $40.40 | -25,000 | 57,171 | -30% | -$1,010,043 | |||||
| D | 2024-08-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $45.19 | -5,000 | 168,702 | -3% | -$225,947 | |||||
| D | 2024-08-06 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $43.35 | -28,000 | 205,043 | -12% | -$1,213,822 | |||||
| D | 2024-07-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $45.01 | -5,000 | 168,702 | -3% | -$225,069 | |||||
| D | 2024-07-09 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $39.93 | -28,000 | 205,043 | -12% | -$1,118,082 | |||||
| D | 2024-06-20 | RNA | Levin Arthur A | Dir | S - Sale+OE | $37.59 | -5,000 | 168,702 | -3% | -$187,951 | |||||
2024-06-18 | RNA | McCarthy Teresa | CHRO | S - Sale | $39.13 | -9,864 | 57,171 | -15% | -$385,972 | ||||||
2024-06-18 | RNA | Maclean Michael F | CFO | S - Sale | $39.13 | -11,228 | 82,865 | -12% | -$439,345 | ||||||
2024-06-18 | RNA | Boyce Sarah | Pres, CEO | S - Sale | $39.13 | -32,074 | 205,043 | -14% | -$1,255,040 | ||||||
2024-06-18 | RNA | Flanagan W. Michael | CSTO | S - Sale | $39.13 | -10,106 | 75,765 | -12% | -$395,445 | ||||||
| D | 2024-06-12 | RNA | Maclean Michael F | CFO | S - Sale+OE | $35.72 | -104,245 | 44,093 | -70% | -$3,723,141 | |||||
| DM | 2024-06-12 | RNA | Levin Arthur A | Dir | S - Sale+OE | $38.07 | -100,000 | 168,702 | -37% | -$3,807,410 | |||||
| DM | 2024-06-12 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $38.63 | -300,000 | 112,117 | -73% | -$11,588,306 | |||||
| D | 2024-06-04 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $27.42 | -28,000 | 112,117 | -20% | -$767,780 | |||||
| D | 2024-05-20 | RNA | Levin Arthur A | Dir | S - Sale+OE | $29.90 | -5,000 | 268,702 | -2% | -$149,481 | |||||
| D | 2024-05-14 | RNA | Maclean Michael F | CFO | S - Sale+OE | $28.28 | -75,000 | 44,093 | -63% | -$2,121,045 | |||||
| D | 2024-05-07 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $25.54 | -28,000 | 112,117 | -20% | -$715,050 | |||||
| D | 2024-04-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $22.82 | -5,000 | 268,702 | -2% | -$114,123 | |||||
2024-04-03 | RNA | Levin Arthur A | Dir | S - Sale | $27.11 | -20,000 | 268,702 | -7% | -$542,214 | ||||||
| D | 2024-04-02 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $26.25 | -28,000 | 112,117 | -20% | -$734,919 | |||||
| D | 2024-03-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $23.97 | -5,000 | 288,702 | -2% | -$119,848 | |||||
| D | 2024-03-13 | RNA | Maclean Michael F | CFO | S - Sale+OE | $24.52 | -40,000 | 44,093 | -48% | -$980,760 | |||||
| D | 2024-03-12 | RNA | Levin Arthur A | Dir | S - Sale+OE | $22.03 | -27,641 | 288,702 | -9% | -$609,017 | |||||
| DM | 2024-03-08 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $21.70 | -112,000 | 112,117 | -50% | -$2,430,392 | |||||
| D | 2024-03-01 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $20.13 | -84,000 | 112,117 | -43% | -$1,691,306 | |||||
2024-01-22 | RNA | Levin Arthur A | Dir | S - Sale | $10.13 | -1,859 | 291,343 | -1% | -$18,832 | ||||||
| D | 2024-01-22 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $10.13 | -5,092 | 44,008 | -10% | -$51,582 | |||||
| D | 2024-01-22 | RNA | Flanagan W. Michael | CSTO | S - Sale+OE | $10.13 | -4,129 | 35,871 | -10% | -$41,827 | |||||
| D | 2024-01-22 | RNA | McCarthy Teresa | CHRO | S - Sale+OE | $10.13 | -2,065 | 17,035 | -11% | -$20,918 | |||||
| D | 2024-01-22 | RNA | Maclean Michael F | CFO | S - Sale+OE | $10.13 | -1,616 | 16,884 | -9% | -$16,370 | |||||
| D | 2023-03-15 | RNA | Levin Arthur A | Dir | S - Sale+OE | $22.01 | -100 | 293,202 | 0% | -$2,201 | |||||
| D | 2023-02-14 | RNA | Levin Arthur A | Chief Scientific Officer | S - Sale+OE | $23.66 | -10,000 | 293,202 | -3% | -$236,567 | |||||
| DM | 2023-02-01 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $24.35 | -50,000 | 53,352 | -48% | -$1,217,727 | |||||
| D | 2023-01-12 | RNA | Levin Arthur A | Chief Scientific Officer | S - Sale+OE | $22.00 | -10,000 | 275,202 | -4% | -$220,028 | |||||
| D | 2022-12-29 | RNA | Levin Arthur A | Chief Scientific Officer | S - Sale+OE | $22.01 | -40,000 | 1,330 | -97% | -$880,568 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |